MX2022002946A - Inhibidores de cdk y su uso como productos farmaceuticos. - Google Patents
Inhibidores de cdk y su uso como productos farmaceuticos.Info
- Publication number
- MX2022002946A MX2022002946A MX2022002946A MX2022002946A MX2022002946A MX 2022002946 A MX2022002946 A MX 2022002946A MX 2022002946 A MX2022002946 A MX 2022002946A MX 2022002946 A MX2022002946 A MX 2022002946A MX 2022002946 A MX2022002946 A MX 2022002946A
- Authority
- MX
- Mexico
- Prior art keywords
- cdk inhibitors
- pharmaceutical products
- cdk
- inhibitors
- directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898839P | 2019-09-11 | 2019-09-11 | |
| US202063005577P | 2020-04-06 | 2020-04-06 | |
| PCT/US2020/050326 WO2021050824A1 (en) | 2019-09-11 | 2020-09-11 | Cdk inhibitors and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002946A true MX2022002946A (es) | 2022-06-14 |
Family
ID=74850746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002946A MX2022002946A (es) | 2019-09-11 | 2020-09-11 | Inhibidores de cdk y su uso como productos farmaceuticos. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20220324830A1 (https=) |
| EP (1) | EP4028005A4 (https=) |
| JP (1) | JP7763489B2 (https=) |
| KR (1) | KR20220079851A (https=) |
| CN (1) | CN114786673A (https=) |
| AU (1) | AU2020345950A1 (https=) |
| BR (1) | BR112022004327A2 (https=) |
| CA (1) | CA3153531A1 (https=) |
| IL (1) | IL291191A (https=) |
| MX (1) | MX2022002946A (https=) |
| WO (1) | WO2021050824A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220079851A (ko) * | 2019-09-11 | 2022-06-14 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk 억제제 및 약제로서의 이의 용도 |
| US12570607B2 (en) | 2019-12-09 | 2026-03-10 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
| CN114605390B (zh) * | 2020-12-04 | 2024-08-16 | 上海凌达生物医药有限公司 | 具有cdk激酶抑制活性的化合物、其药物组合物和用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| WO2022247796A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| US20230144528A1 (en) * | 2021-09-30 | 2023-05-11 | Prelude Therapeutics Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| KR20240115816A (ko) | 2021-10-14 | 2024-07-26 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk9 억제제로서 작용하는 치환된 벤즈이미다졸의 결정질 형태 및 이의 용도 |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2025189114A1 (en) | 2024-03-08 | 2025-09-12 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2026024933A1 (en) * | 2024-07-24 | 2026-01-29 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| CN119638640A (zh) * | 2024-12-10 | 2025-03-18 | 杭州亦宁医药技术有限公司 | 一种5-溴-2-甲基-3-异丙基-吲唑的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010508301A (ja) | 2006-10-31 | 2010-03-18 | スミスクライン ビーチャム コーポレーション | ５−置換及び６−置換ベンゾイミダゾールチオフェン化合物 |
| CN103083643B (zh) | 2008-03-27 | 2015-01-07 | 雀巢产品技术援助有限公司 | 增加肽、肽模拟物和其他胃肠道转运蛋白底物吸收的方法 |
| CN102471339A (zh) * | 2009-07-15 | 2012-05-23 | 雅培制药有限公司 | 激酶的吡咯并吡啶抑制剂 |
| WO2014137728A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| EP2970200A1 (en) * | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| WO2015108861A1 (en) * | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| JP2017523214A (ja) * | 2014-08-05 | 2017-08-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロ環キナーゼ阻害剤 |
| WO2016197078A1 (en) * | 2015-06-05 | 2016-12-08 | Syros Pharmaceuticals, Inc. | Compounds for the modulation of myc activity |
| ES2728356T3 (es) * | 2015-06-29 | 2019-10-23 | Astrazeneca Ab | Derivados de amidas policíclicas como inhibidores de CDK9 |
| WO2017051262A1 (en) | 2015-09-22 | 2017-03-30 | Hindustan Petroleum Corporation Limited | An additive and a catalyst composition comprising the additive for fcc process |
| FR3041639B1 (fr) * | 2015-09-30 | 2019-01-25 | Les Laboratoires Servier | NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
| CN107641118B (zh) * | 2016-07-22 | 2020-11-06 | 爱科诺生物医药股份有限公司 | 具有细胞坏死抑制活性的化合物及其组合物和应用 |
| KR20220079851A (ko) * | 2019-09-11 | 2022-06-14 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk 억제제 및 약제로서의 이의 용도 |
| US12570607B2 (en) * | 2019-12-09 | 2026-03-10 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
| WO2022035799A1 (en) * | 2020-08-10 | 2022-02-17 | Prelude Therapeutics Incorporated | Heterocycle cdk inhibitors and their use thereof |
| US11685744B2 (en) * | 2020-09-21 | 2023-06-27 | Prelude Therapeutics Incorporated | CDK inhibitors and their use as pharmaceuticals |
| CA3205652A1 (en) * | 2020-12-18 | 2022-06-23 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| US20230144528A1 (en) * | 2021-09-30 | 2023-05-11 | Prelude Therapeutics Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| KR20240115816A (ko) * | 2021-10-14 | 2024-07-26 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk9 억제제로서 작용하는 치환된 벤즈이미다졸의 결정질 형태 및 이의 용도 |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
-
2020
- 2020-09-11 KR KR1020227011706A patent/KR20220079851A/ko not_active Ceased
- 2020-09-11 US US17/642,482 patent/US20220324830A1/en not_active Abandoned
- 2020-09-11 BR BR112022004327A patent/BR112022004327A2/pt unknown
- 2020-09-11 AU AU2020345950A patent/AU2020345950A1/en active Pending
- 2020-09-11 US US17/018,005 patent/US11673893B2/en active Active
- 2020-09-11 JP JP2022515905A patent/JP7763489B2/ja active Active
- 2020-09-11 EP EP20864098.7A patent/EP4028005A4/en not_active Withdrawn
- 2020-09-11 MX MX2022002946A patent/MX2022002946A/es unknown
- 2020-09-11 CN CN202080078041.6A patent/CN114786673A/zh active Pending
- 2020-09-11 CA CA3153531A patent/CA3153531A1/en active Pending
- 2020-09-11 WO PCT/US2020/050326 patent/WO2021050824A1/en not_active Ceased
-
2022
- 2022-03-08 IL IL291191A patent/IL291191A/en unknown
-
2023
- 2023-04-04 US US18/295,394 patent/US12486277B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12486277B2 (en) | 2025-12-02 |
| JP2022548568A (ja) | 2022-11-21 |
| CA3153531A1 (en) | 2021-03-18 |
| EP4028005A1 (en) | 2022-07-20 |
| EP4028005A4 (en) | 2023-09-20 |
| IL291191A (en) | 2022-05-01 |
| AU2020345950A1 (en) | 2022-03-31 |
| US11673893B2 (en) | 2023-06-13 |
| KR20220079851A (ko) | 2022-06-14 |
| CN114786673A (zh) | 2022-07-22 |
| BR112022004327A2 (pt) | 2022-05-31 |
| US20230242543A1 (en) | 2023-08-03 |
| WO2021050824A1 (en) | 2021-03-18 |
| JP7763489B2 (ja) | 2025-11-04 |
| US20210070761A1 (en) | 2021-03-11 |
| US20220324830A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002946A (es) | Inhibidores de cdk y su uso como productos farmaceuticos. | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| MX2020001598A (es) | Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5). | |
| MX2023004037A (es) | Compuestos biciclicos como inhibidores alostericos de shp2. | |
| PH12020550857A1 (en) | Polycyclic compounds as allosteric shp2 inhibitors | |
| BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
| MX2019011764A (es) | Composiciones limpiadoras y usos de las mismas. | |
| MX2020001270A (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39. | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| MX2019008696A (es) | Compuestos de piridina como inhibidores de shp2 alostericos. | |
| MX2023007265A (es) | Inhibidores de cdk y su uso como productos farmacéuticos. | |
| CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
| MY197720A (en) | Bicyclic heterocycles as fgfr inhibitors | |
| EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
| UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
| MX372914B (es) | Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo. | |
| UA115677C2 (uk) | ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ | |
| MX2018007075A (es) | Compuestos policiclicos como inhibidores de tirosina quinasa de bruton. | |
| MX386700B (es) | Inhibidores de la tirosina quinasa de bruton y metodos de su uso. | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| WO2015019198A3 (en) | High potency pancreatin pharmaceutical compositions | |
| MX382832B (es) | Benzimidazoles sustituidos, su preparación y su uso como productos farmacéuticos. | |
| EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
| ZA202002779B (en) | Dantrolene prodrugs and methods of their use | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. |